1. Home
  2. CMC vs BLCO Comparison

CMC vs BLCO Comparison

Compare CMC & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commercial Metals Company

CMC

Commercial Metals Company

HOLD

Current Price

$61.65

Market Cap

6.8B

Sector

Industrials

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.07

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMC
BLCO
Founded
1915
1853
Country
United States
Canada
Employees
12690
N/A
Industry
Steel/Iron Ore
Ophthalmic Goods
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.0B
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
CMC
BLCO
Price
$61.65
$16.07
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$71.20
$18.55
AVG Volume (30 Days)
1.1M
451.6K
Earning Date
03-26-2026
04-29-2026
Dividend Yield
1.17%
N/A
EPS Growth
N/A
N/A
EPS
1.58
N/A
Revenue
$7,918,430,000.00
$5,101,000,000.00
Revenue This Year
$17.96
$8.61
Revenue Next Year
$6.71
$5.52
P/E Ratio
$38.93
N/A
Revenue Growth
25.57
6.47
52 Week Low
$37.92
$10.45
52 Week High
$84.87
$18.92

Technical Indicators

Market Signals
Indicator
CMC
BLCO
Relative Strength Index (RSI) 24.49 36.18
Support Level $55.52 $14.39
Resistance Level $71.99 $17.66
Average True Range (ATR) 2.26 0.51
MACD -0.87 -0.20
Stochastic Oscillator 5.90 4.51

Price Performance

Historical Comparison
CMC
BLCO

About CMC Commercial Metals Company

Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: